High levels of cathepsin D and cystatin B were associated with incident coronary events (HR 1.34 and HR 1.26, respectively), but these associations did not remain significant after adjusting for smoking.
Case-Control (n=793)
Are elevated plasma levels of cathepsin D, cathepsin L, and cystatin B associated with an increased risk of incident coronary events?
Elevated plasma levels of cathepsin D and cystatin B are associated with incident coronary events, though this association appears to be heavily confounded by smoking status.
Effect estimate: HR 1.34 (95% CI 1.02 to 1.75)
OBJECTIVE: The majority of acute coronary syndromes are caused by plaque ruptures. Proteases secreted by macrophages play an important role in plaque ruptures by degrading extracellular matrix proteins in the fibrous cap. Matrix metalloproteinases have been shown to be markers for cardiovascular disease whereas the members of the cathepsin protease family are less studied. METHODS: Cathepsin D, cathepsin L and cystatin B were measured in plasma at baseline from 384 individuals who developed coronary events (CEs), and from 409 age-matched and sex-matched controls from the Malmö Diet and Cancer cardiovascular cohort. RESULTS: Cathepsin D (180 (142-238) vs 163 (128-210), p<0.001), cathepsin L (55 (44-73) vs 52 (43-67), p<0.05) and cystatin B levels (45 (36-57) vs 42 (33-52), p<0.001) were significantly increased in CE cases compared to controls. In addition, increased cathepsin D (220 (165-313) vs 167 (133-211), p<0.001), cathepsin L (61 (46-80) vs 53 (43-68), p<0.05) and cystatin B (46 (38-58) vs 43 (34-54), p<0.05) were associated with prevalent diabetes. Furthermore, cathepsin D and cystatin B were increased in smokers. The HRs for incident CE comparing the highest to the lowest tertile(s) of cathepsin D and cystatin B were 1.34 (95% CI 1.02 to 1.75) and 1.26 (95% CI 1.01 to 1.57), respectively, after adjusting for age, sex, low-density lipoprotein/high-density lipoprotein ratio, triglycerides, body mass index, hypertension and glucose, but these associations did not remain significant after further addition of smoking to the model. In addition, cathepsin D was increased in incident CE cases among smokers after adjusting for cardiovascular risk factors. CONCLUSIONS: The associations of cathepsin D and cystatin B with future CE provide clinical support for a role of these factors in cardiovascular disease, which for cathepsin D may be of particular importance for smokers.
Gonçalves et al. (Fri,) conducted a case-control in Coronary events (n=793). Cathepsin D, cathepsin L, and cystatin B vs. Lowest tertile / Controls was evaluated on Incident coronary events (HR 1.34, 95% CI 1.02 to 1.75). High levels of cathepsin D and cystatin B were associated with incident coronary events (HR 1.34 and HR 1.26, respectively), but these associations did not remain significant after adjusting for smoking.